Xencor reported $-30.52M in EBITDA for its fiscal quarter ending in June of 2025.





Ebitda Change Date
AbbVie USD 4.34B 56M Jun/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Amgen USD 5.91B 2.31B Sep/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
AstraZeneca USD 4.96B 127M Jun/2025
Biogen USD 1.01B 456.5M Jun/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Cytokinetics USD -107.82M 45.51M Jun/2025
GlaxoSmithKline GBP 3.18B 45M Jun/2025
J&J USD 9.52B 389M Sep/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Novartis USD 5.88B 290M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Xencor USD -30.52M 6.39M Jun/2025